Time New York: Tue 11 Dec 08:57 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Weakness Seen in EMCORE (EMKR) Estimates: Should You Stay Away?

Zacks

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is EMCORE Corporation EMKR, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in EMKR.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen two estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from 30 cents a share a month ago to its current level of 3 cents.

Also, for the current quarter, EMCORE has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 5 cents a share from earnings of 4 cents over the past 30 days.


The stock also has seen some pretty dismal trading lately, as the share price has dropped 14.8% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Electronics – Manufacturing Machinery industry, you may instead consider a better-ranked stock – Entegris, Inc. ENTG. The stock currently holds a Zacks Rank #2 (Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.